Labcorp launches ptau217 blood biomarker test to accelerate path to diagnosis of alzheimer's disease and support clinical trials

Addition of ptau217 test further expands the company's leadership in testing options for alzheimer's disease to improve patient care  burlington, n.c. , march 20, 2024 /prnewswire/ -- labcorp (nyse: lh), a global leader of innovative and comprehensive laboratory services, announced today the launch and immediate availability of its test to identify the presence or absence of phosphorylated tau 217 (ptau217), a pivotal blood biomarker designed to aid in the diagnosis of alzheimer's disease and the subsequent monitoring of patients undergoing treatment with new alzheimer's disease therapies.
LH Ratings Summary
LH Quant Ranking